Lihua Yu, Ph.D.
As FogPharma’s chief data officer, Lihua Yu is responsible for the development and implementation of data science strategy across all R&D functions and research programs, as well as establishing digital and machine learning platform to power the design-make-test-predict cycle of the company’s proprietary Helicon™ discovery platform. Lihua brings more than 20 years of experience and leadership in data science across computational biology, cancer genomics, research informatics, clinical genomics, real world data and evidence.
Prior to joining FogPharma, Lihua was the president and chief data science officer at H3 Biomedicine and served in multiple roles during her tenure of nearly a decade. She established H3 as a bioinformatics powerhouse studying splicing regulation in cancer, and is recognized with AACR 2020 Team Science Awards for their contribution to Pan-Cancer Atlas. At H3, she held overall responsibilities for the company’s R&D and was responsible for driving the expanded use of data and technology and leading the creation of a data science/cancer genomics/information-sharing engine supporting all phases of drug discovery and early clinical development. Lihua led H3 during its transition from a drug discovery company to an early phase drug development company. Prior to H3, she was the cancer bioinformatics leader at AstraZeneca and held roles of increasing responsibility from 2000 to 2011.
Lihua holds a Ph.D. in biomedical engineering from Boston University working under Dr. Temple Smith, and her M.S. and B.S. in biomedical engineering from Tsinghua University in Beijing, China.